Opioid Tolerance Treatment Market was valued at US$ 1.82 Bn. in 2022, and it is expected to reach US$ 2.32 Bn. by 2029, exhibiting a CAGR of 3.51 % during the forecast period 2023-2029.Opioid Tolerance Treatment Market Overview:
Opioids are drugs used to treat severe or persistent pain, such as chronic headaches and backaches, as well as by people recovering from surgery or dealing with severe cancer-related pain, as well as by adults and children who have suffered serious injuries in falls, car accidents, or other incidents or while playing sports. Opioids are classified as drugs as well. Depending on the patient, the circumstance, and the type and amount of pain, doctors may prescribe a variety of opioids in a range of strengths that can be taken in a variety of ways.To know about the Research Methodology :- Request Free Sample Report The report explores the Opioid Tolerance Treatment Market's segments (Drug, Opioid Tolerance, Route of Administration, and End-User Region). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2020. The report investigates the Opioid Tolerance Treatment Market’s drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Opioid Tolerance Treatment Market’s contemporary competitive scenario.
Opioid Tolerance Treatment Market Dynamics:
Opioid therapy is widely used in the treatment of persistent cancer and severe pain. Their excellent efficacy is one factor in their widespread use. When these are used for a longer period of time, there are occasionally unfavorable implications identified. Therapy has less of an impact, and people respond to it less enthusiastically. Such patients need NMDA antagonists or greater doses. Occasionally, alpha2-adrenoceptor agonists are used. When someone regularly uses opioids, they may have the condition known as opioid tolerance. The body adapts to the presence of opioids over time and no longer reacts to them the same way. This may result in the need for higher doses of opioids to have the same impact as before. For those who depend on opioids for pain treatment or other medical needs, opioid tolerance is a serious issue because it can result in addiction and potentially lethal overdoses. According to a thorough research the industry for opioid tolerance treatment will extend the opportunities available to market players with moderate market development. The evaluation period for the growth, from 2022 to 2029, would also show an increase in market valuation. Opioids are powerful painkillers that are administered to patients with chronic cancer and excruciating pain. These opioids are often only taken temporarily. Patients develop an opioid tolerance if these opioids are prescribed or taken more frequently or for a longer period of time, which prevents them from experiencing the desired analgesic or therapeutic response. Higher opioid doses are needed to treat people in such circumstances. Other opioid therapy alternatives, like NMDA antagonists and alpha2-adrenoceptor agonists, can be used to treat opioid-tolerant patients. These medications give opioid-tolerant patients or those with opioid tolerance the therapeutic response they need. Drivers: Due to increased opioid use for both medical and non-medical purposes as well as an increase in the number of opioid prescriptions written for therapeutic purposes, which can result in opioid tolerance if taken for an extended period of time, the market for opioid tolerance treatment is growing rapidly. Additionally, ongoing clinical trials, numerous studies being conducted for opioid tolerant treatment by various research institutes & firms, rising drug misuse, and drug overdose occurrences are some of the primary factors causing the opioid tolerance treatment market to grow. Drug misuse is becoming more prevalent in all nations and societies. The countries that are close to the Golden Crescent and Golden Triangle, areas in the Asia Pacific region known for illicit opium cultivation, are some of the territories that are facing a threat from opium use. Through research and development and the creation of better treatments, the government and medical community are attempting to combat this, creating the conditions for market expansion. There is a substantial pipeline of treatments for tolerance on the market, and more ongoing trials are in progress. As a result, during the course of the projection period, the market for treating opioid tolerance will rise. One of the main drivers of growth will be the use in healthcare. Due to increased opioid use for therapeutic and non-therapeutic uses, as well as increased opioid prescriptions, which can cause opioid tolerance if taken for an extended period of time, the market for opioid tolerance treatment is growing significantly. Additional factors driving the growth of the opioid tolerance treatment market include ongoing clinical studies, various research projects being conducted for opioid tolerant therapy by different research institutes and companies, rising drug misuse, and an increase in drug overdose instances. Restrain: Digestive issues: When a patient begins taking opioids, they may have constipation, nausea, and vomiting. Grogginess, sluggish reflexes, or difficulty concentrating. Opioid addiction and tolerance: The patient may get addicted to opioids and require more of the medicine to relieve pain. Additionally, long-term opioid use can lead to dependency, and whenever the patient stops taking the prescription, they may experience withdrawal symptoms such anxiety, irritability, drug cravings, tremors, and others. Additionally, market participants are concentrating on releasing non-opioid pain relief medicines, which is anticipated to slow market growth. For instance, the non-opioid post-operative pain medication Maxigesic IV was introduced to the European market by the speciality biopharmaceutical business Hyloris Pharmaceuticals SA in July 2022. Opportunities: The rising incidence of chronic pain, the rising number of surgical procedures, and the rising number of product approvals are the key drivers propelling the expansion of the global market for opioid tolerance treatment. But some of the issues limiting the growth of this market are the high cost of these therapies and the lack of awareness of these treatments. COVID-19 Impact Opioid Tolerance Treatment Market: The COVID-19 pandemic has had an influence on the whole healthcare supply chain, mostly as a result of the extreme lockdown in some areas. The COVID-19 epidemic has had three main effects on the economies of different parts of the world: 1) a direct influence on supply and demand; 2) disruptions in the distribution system; and 3) a financial impact on businesses and financial markets. Transportation and distribution of medical supplies are issues in a number of nations, including Thailand, Indonesia, and Singapore. Over the past few months, the majority of sectors in the world have suffered. This can be ascribed to the enormous disruptions that various precautionary lockdowns and other limitations that were imposed by governing agencies around the world caused in their respective production and supply-chain operations. The same is true for the global market for opioid tolerance treatments. Additionally, as the overall economic situation of the majority of people has been significantly impacted by this outbreak, consumer demand has also subsequently decreased as people are now more eager to cut non-essential expenses from their particular budgets. Over the course of the forecast period, the aforementioned factors are anticipated to have a negative impact on the revenue trajectory of the global market for opioid tolerance treatments. The global market for opioid tolerance treatments is anticipated to rebound, nevertheless, when the relevant governing bodies start to relax these enforced lockdowns.Global Opioid Tolerance Treatment Market Segment Analysis:
Based on Drug, Alpha2-adrenoceptor Agonists is dominating the market with highest CAGR during the forecast period. Approximately 84.0 percent of the market is accounted for by the medicine. This undisputed domination is the result of the medications' rising popularity, which is also due to the fact that they have few or no negative effects. Due to these advantages, alpha2-adrenoceptor agonists have dominated the pharmacological market for the treatment of opioid tolerance over the aforementioned time period.Based on Opioid Tolerance, Acquired Tolerance segment is dominating the market with highest CAGR during the forecast period. Due to an increase in medication dosage and amount as well as long-term opioid use, the market is projected to grow at a significant CAGR during the forecast period. Based on the Route of Administration, Parenteral segment is dominating the market with highest CAGR during the forecast period. This market is being driven by variables including higher bioavailability and a quicker onset of effect. Based on the end user, Hospitals & ASCs segment is dominating the market with highest CAGR during the forecast period. Due to the increased number of patients admitted for cancer, chronic pain, and better amenities offered at these settings, the hospitals & ASCs sector dominated the global opioid tolerance therapy market.
Opioid Tolerance Treatment Market Regional Insights:
The North America region dominated the market with xx % share in 2022. The North America region is expected to witness significant growth at a CAGR of xx% through the forecast period. Due to the high incidence of chronic diseases and the pain they cause, as well as the region's aging population, which is more sensitive to pain and requires a high dose of opioids for pain management, North America held the highest share of the global market for opioid tolerance treatment in 2018. By 2060, there will be approximately 98 million Americans who are 65 years of age or older, according to projections. This indicates that in the next years, North America's market for treating opioid tolerance is anticipated to expand significantly. Furthermore, the misuse of opioids is being fuelled by the rising rate of opioid prescriptions. The U.S. has recorded a higher death rate from opioid overdose. The market for opioids tolerance treatments in the area is expanding as a result of rising awareness and a growing necessity for such treatments. In terms of market share, the Asia Pacific region is anticipated to have rapid expansion in the global opioid tolerance therapy market throughout the anticipated timeframe. This can be ascribed to an increase in the prevalence of chronic diseases, a decline in the number of regulatory regulations governing the prescription of opioids in the area, and a lack of public understanding of the serious adverse effects of these prescriptions. The Asia Pacific market for opioid tolerance treatment is, nevertheless, being driven by increased government funding for raising regional awareness about opioids. Additionally, the Asia Pacific region's high cancer incidence rate and Japan's big senior population are both driving up demand for opioid tolerance medications. The objective of the report is to present a comprehensive analysis of the Global Opioid Tolerance Treatment Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Opioid Tolerance Treatment Market dynamic, structure by analyzing the market segments and projecting the Global Opioid Tolerance Treatment Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Opioid Tolerance Treatment Market make the report investor’s guide.Global Opioid Tolerance Treatment Market Scope: Inquire before buying
Global Opioid Tolerance Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 1.82 Bn. Forecast Period 2023 to 2029 CAGR: 3.51% Market Size in 2029: US$ 2.32 Bn. Segments Covered: by Drug NMDA Antagonists Ketamine Dextromethorphan Others (including Guaifenisin) Alpha2-adrenoceptor Agonists Clonidine Tizanidne Others (including Lofexidine) Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs) by Opioid Tolerance Innate Tolerance Acquired Tolerance by Route of Administration Enteral Parenteral Others (including Transdermal Route, Patches, and Cartons of Patches) by End-User Hospitals & ASCs Rehabilitation Centers Others (including Home Care Settings and Research Institutes) Opioid Tolerance Treatment Market by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Opioid Tolerance Treatment Market Key Players
1. Boehringer Ingelheim International GmbH 2. GlaxoSmithKline plc. 3. Teva Pharmaceutical Industries Ltd. 4. Mylan N.V. 5. Otsuka Pharmaceutical Co. Ltd. 6. Johnson & Johnson Services 7. Aurobindo Pharma 8. Pfizer Inc. 9. Acorda Therapeutics, Inc. 10.Zydus Cadila 11.Janssen Pharmaceuticals, Inc., 12.Actavis Plc., 13.Sanofi, 14.Sun Pharmaceutical Industries Ltd., 15.Mallinckrodt Pharmaceuticals, 16.Endo Pharmaceuticals Inc. 17.Zyla Life Sciences. Frequently Asked Questions: 1] What segments are covered in the Global Opioid Tolerance Treatment Market report? Ans. The segments covered in the Global Opioid Tolerance Treatment Market report are based on Drug, Opioid Tolerance, Route of Administration, and End-User. 2] Which region is expected to hold the highest share in the Global Opioid Tolerance Treatment Market? Ans. North America region is expected to hold the highest share in the Global Opioid Tolerance Treatment Market. 3] What is the market size of the Global Opioid Tolerance Treatment Market by 2029? Ans. The market size of the Global Opioid Tolerance Treatment Market by 2029 is expected to reach US$ 2.24 Bn. 4] What is the forecast period for the Global Opioid Tolerance Treatment Market? Ans. The forecast period for the Global Opioid Tolerance Treatment Market is 2023-2029. 5] What was the market size of the Global Opioid Tolerance Treatment Market in 2022? Ans. The market size of the Global Opioid Tolerance Treatment Market in 2022 was valued at US$ 1.82 Bn.
1. Global Opioid Tolerance Treatment Market: Research Methodology 2. Global Opioid Tolerance Treatment Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Opioid Tolerance Treatment Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Opioid Tolerance Treatment Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Opioid Tolerance Treatment Market Segmentation 4.1 Global Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) • Innate Tolerance • Acquired Tolerance 4.2 Global Opioid Tolerance Treatment Market, By Drug (2022-2029) • NMDA Antagonists o Ketamine o Dextromethorphan o Others (including Guaifenisin) • Alpha2-adrenoceptor Agonists o Clonidine o Tizanidne o Others (including Lofexidine) • Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs) 4.3 Global Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) • Enteral • Parenteral • Others (including Transdermal Route, Patches, and Cartons of Patches) 4.4 Global Opioid Tolerance Treatment Market, By End user (2022-2029) • Hospitals & ASCs • Rehabilitation Centers • Others (including Home Care Settings and Research Institutes) 5 North America Opioid Tolerance Treatment Market (2022-2029) 5.1 North America Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) • Innate Tolerance • Acquired Tolerance 5.2 North America Opioid Tolerance Treatment Market, By Drug (2022-2029) • NMDA Antagonists o Ketamine o Dextromethorphan o Others (including Guaifenisin) • Alpha2-adrenoceptor Agonists o Clonidine o Tizanidne o Others (including Lofexidine) • Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs) 5.3 North America Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) • Enteral • Parenteral • Others (including Transdermal Route, Patches, and Cartons of Patches) 5.4 North America Opioid Tolerance Treatment Market, By End user (2022-2029) • Hospitals & ASCs • Rehabilitation Centers • Others (including Home Care Settings and Research Institutes) 5.5 North America Opioid Tolerance Treatment Market, by Country (2022-2029) • United States • Canada • Mexico 6 Asia Pacific Opioid Tolerance Treatment Market (2022-2029) 6.1. Asia Pacific Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) 6.2. Asia Pacific Opioid Tolerance Treatment Market, By Drug (2022-2029) 6.3. Asia Pacific Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) 6.4. Asia Pacific Opioid Tolerance Treatment Market, By End user (2022-2029) 6.5. Asia Pacific Opioid Tolerance Treatment Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7 Middle East and Africa Opioid Tolerance Treatment Market (2022-2029) 7.1 Middle East and Africa Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) 7.2. Middle East and Africa Opioid Tolerance Treatment Market, By Drug (2022-2029) 7.3. Middle East and Africa Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) 7.4. Middle East and Africa Opioid Tolerance Treatment Market, By End user (2022-2029) 7.5. Middle East and Africa Opioid Tolerance Treatment Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8 South America Opioid Tolerance Treatment Market (2022-2029) 8.1. South America Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) 8.2. South America Opioid Tolerance Treatment Market, By Drug (2022-2029) 8.3. South America Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) 8.4. South America Opioid Tolerance Treatment Market, By End user (2022-2029) 8.5. South America Opioid Tolerance Treatment Market, by Country (2022-2029) • Brazil • Argentina • Rest of South America 9 European Opioid Tolerance Treatment Market (2022-2029) 9.1. European Opioid Tolerance Treatment Market, By Opioid Tolerance (2022-2029) 9.2. European Opioid Tolerance Treatment Market, By Drug (2022-2029) 9.3. European Opioid Tolerance Treatment Market, By Route of Administration (2022-2029) 9.4. European Opioid Tolerance Treatment Market, By End user (2022-2029) 9.5. European Opioid Tolerance Treatment Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest of Europe 10 Company Profile: Key players 10.1. Boehringer Ingelheim International GmbH 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 GlaxoSmithKline plc. 10.3 Teva Pharmaceutical Industries Ltd. 10.4 Mylan N.V. 10.5 Otsuka Pharmaceutical Co. Ltd. 10.6 Johnson & Johnson Services 10.7 Aurobindo Pharma 10.8 Pfizer Inc. 10.9 Acorda Therapeutics, Inc. 10.10 Zydus Cadila 10.11 Janssen Pharmaceuticals, Inc., 10.12 Actavis Plc., 10.13 Sanofi, 10.14 Sun Pharmaceutical Industries Ltd., 10.15 Mallinckrodt Pharmaceuticals, 10.16 Endo Pharmaceuticals Inc. 10.17 Zyla Life Sciences.